A beacon of innovation has emerged from the serene shores of Lugano, as InVirtuoLabs secures €2.85 million in its inaugural funding round. This Swiss biotech pioneer, dedicated to reshaping the future of pharmaceuticals, is set to harness artificial intelligence to slash the staggering costs and timelines that have long burdened drug development. With this capital, InVirtuoLabs aims to make life-changing treatments more accessible, targeting a landscape where innovation meets urgent human need.
Founded by visionaries Gianvito Grasso and Sertac Yeltekin, InVirtuoLabs blends cutting-edge machine learning with sophisticated molecular simulations to unearth and refine drug candidates at unprecedented speed. Their proprietary Next Generation Virtual Lab stands as a testament to their ingenuity, leveraging AI to sift through billions of molecular possibilities and pinpoint those with the greatest promise. “The fusion of artificial intelligence, chemistry, and molecular biophysics is transforming drug development,” said Gianvito Grasso, CEO of InVirtuoLabs and a distinguished researcher at IDSIA–Dalle Molle Institute for Artificial Intelligence (USI-SUPSI). “Our system doesn’t just analyze—it creates, tests, and perfects new molecules with a focus on efficacy and safety, especially for rare diseases crying out for solutions.”
The company’s ambitions are as bold as they are practical. Over the next 18 months, InVirtuoLabs plans to amplify its team, forge strategic partnerships, and enhance its platform’s capabilities. Already, they’ve notched a landmark achievement: a novel protocol targeting nuclear receptors—vital proteins tied to over 100 diseases, from metabolic disorders to certain cancers. By zeroing in on receptors linked to widespread metabolic conditions, InVirtuoLabs is accelerating the path to new therapies, potentially halving the 12-year average development timeline and trimming costs that often exceed €2.4 billion per drug.
Demet Olesen, Chief Commercial Officer at InVirtuoLabs, emphasized their real-world focus: “From day one, we’ve refined our models through dialogue with biotech and pharma firms of all scales. These collaborations sharpen our tech and ensure we’re tackling industry challenges head-on, keeping us at the forefront of delivering groundbreaking solutions.” Grasso added a rallying cry: “Our vision is to democratize access to cutting-edge therapies, making drug discovery faster, more precise, and sustainable.” This clarity of purpose underscores InVirtuoLabs’s commitment to doubling success rates over traditional methods, a feat that could redefine pharmaceutical progress.
Editorial Perspective: A Catalyst for Change in Biotech
InVirtuoLabs is poised to leave an indelible mark on an industry ripe for disruption. The pharmaceutical sector has long grappled with inefficiencies—sky-high costs and protracted timelines that delay relief for millions. By wielding AI to explore uncharted chemical spaces, InVirtuoLabs offers a glimpse of a future where rare diseases, often overlooked due to their complexity, find viable treatments sooner. Their emphasis on nuclear receptors—a linchpin in metabolic and oncological research—positions them as a vital player in addressing some of humanity’s most pressing health challenges.
Beyond technology, their strategic roadmap signals a broader impact. Scaling up through partnerships and talent acquisition reflects a savvy understanding of biotech’s collaborative nature. As AI continues to permeate drug discovery, InVirtuoLabs’s approach—rooted in precision and accessibility—aligns with a global shift toward smarter, more equitable healthcare solutions. If they sustain this trajectory, their work could not only streamline R&D but also inspire a wave of innovation, proving that small teams with big ideas can shift paradigms and deliver hope where it’s needed most.
For further assistance or corrections, please reach out to editor@thetimesmag.com.
